Huachuang Synthetic Pharmaceutical

Shaanxi Huachuang Synthetic Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, and commercial-scale production of high-value Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The company distinguishes itself through a technology-driven approach, utilizing a proprietary platform for green chemical synthesis, enzymatic catalysis, and asymmetric synthesis. Its product portfolio primarily targets metabolic diseases, particularly type 2 diabetes, with a strong focus on Dipeptidyl peptidase 4 (DPP4) inhibitors such as Sitagliptin and Vildagliptin. Additionally, Huachuang provides comprehensive CDMO services, supporting global pharmaceutical clients from process optimization to large-scale GMP manufacturing. Headquartered in Xi'an, the company is recognized as a key player in the regional life sciences sector, contributing to the development of cost-effective and sustainable drug manufacturing processes.